Coming Soon: Drugs to Suit Your Genetic Profile (India)
This article was originally published in PharmAsia News
Executive Summary
Indian scientist Sandeep Saxena has developed a new type of test that will allow doctors to adjust drug combinations and dosages to suit a particular patient's genetic profile. So far, Saxena's company, Acto Biotech, has already developed genetic testing for two essential drugs - six mercaypourine and five flurouracil. These two drugs are necessary to fight certain cancers and autoimmune disorders like rheumatoid arthritis. They can, however, result in high toxicity and serious side effects for some patients. Acton Biotech's genetic profiling will allow doctors to minimize toxicity and create the most efficient drug regimen for each patient. Researchers are hopeful that as more tests become available, genetically tailored medicine will help save lives by predicting drug reactions and creating personalized dosages. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.